AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Coya Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Z4HBCC8
3.94▼ 0.20 (-4.83%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
4.14
Day's Range
3.94 – 4.25
52-Week Range
3.71 – 7.50
Volume
186.4K
Avg Volume
152.8K
Share Statistics
Shares Outstanding
Employees
8
Exchange
XNAS
Listed
2022-12-29
Share count as of August 7, 2026

Coya Therapeutics, Inc. Common Stock (COYA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Coya Therapeutics, Inc. Common Stock (COYA)
What is Coya Therapeutics, Inc. Common Stock's Market Cap?
Coya Therapeutics, Inc. Common Stock's Market Cap is $92.4M, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's Enterprise Value?
Coya Therapeutics, Inc. Common Stock's Enterprise Value is $49.2M, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's Price / Sales?
Coya Therapeutics, Inc. Common Stock's Price / Sales is 11.5×, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's EV / Revenue?
Coya Therapeutics, Inc. Common Stock's EV / Revenue is 6.1×, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's EV / EBITDA?
Coya Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's Revenue (TTM)?
Coya Therapeutics, Inc. Common Stock's Revenue (TTM) is $8.0M, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's Net Income (TTM)?
Coya Therapeutics, Inc. Common Stock's Net Income (TTM) is -$21.7M, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's EBITDA?
Coya Therapeutics, Inc. Common Stock's EBITDA is -$23.1M, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Coya Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.92, based on as-reported figures from SEC (XBRL) filings.
What is Coya Therapeutics, Inc. Common Stock's EBITDA Margin?
Coya Therapeutics, Inc. Common Stock's EBITDA Margin is -288.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · COYAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue
YoY growth+49.0%-2.6%+202768.8%—
Operating expenses:
Research and development
In-process research and development
General and administrative
Depreciation
Total operating expenses
% of revenue2991.1%3142.1%252.3%168.3%
Loss from operations
% of revenue-2891.1%-3042.1%-152.3%-68.3%
Other income:
Other income
Pre-tax loss——
Income tax expense————
Net loss
% of revenue-2723.4%-2869.6%-144.2%-59.4%
Net loss per share of common stock, basic
Net loss per share of common stock, diluted